西利宾胺在肺结核治疗中护肝疗效  

Protective effect of Silybin Meglumine on liver-injury in the treatment of pulmonary tuberculosis

作　　者：朱杰[1] 余连锋[1] 王良玉[1] 陈铁军 

机构地区：[1]浙江省慈溪市疾病预防控制中心,浙江慈溪315300 [2]慈溪市中医医院结核门诊

出　　处：《现代预防医学》2012年第12期3104-3105,共2页Modern Preventive Medicine

摘　　要：目的观察西利宾胺在肺结核治疗中护肝疗效。方法采用西利宾胺和世界卫生组织推荐的短化方案治疗608例单纯菌阳肺结核(治疗组),并以同期短化治疗的552例作为对照(对照组)。结果治疗组初、复治菌阳肺结核患者肝功损害率分别为2.35%、5.10%,对照组分别为4.19%、18.18%,前两者差异无统计学意义(P﹥0.05),后两者差异有统计学意义(P﹤0.01)。结论在初治单纯肺结核时,无需常规加用护肝药,复治治疗则需考虑联用护肝药。OBJECTIVE To observe the protective effect of Silybin Meglumine on liver-injury occurring in the course of pul- monary tuberculosis treatment. METHODS 608 simple smear-positive patients （treated group） were administrated with the combination of Silybin Meglumine and short-course chemotherapy of the WHO, while 552 patients （control group） were received short-course chemotherapy. RESULTS The incidence of liver function impairment of initial treatment patients was 2.35% in the treated group and 4.19% in the retreatment patients （P〉 0.05）. However, the rates in the control group were 5.10% and 18.18%, respectively （P〈 0.01 ）. CONCLUSION Liver protective agent is not necessary for simple pulmonary tuberculosis patients during initial treatment, while during retreatment, which is considered to be necessary.

关 键 词：结核 肺 护肝 西利宾胺 

分 类 号：R521[医药卫生—内科学]